Vanda Pharmaceuticals | VNDA - Gross Profit On Sales


Vanda Pharmaceuticals reported $50.6M in Gross Profit on Sales for its fiscal quarter ending in December of 2024.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 75.25M 1.52M Jun/2026
AstraZeneca USD 12.86B 251M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Insmed USD 356.19M 99.73M Jun/2026
J&J USD 18.55B 6M Sep/2026
Lexicon Pharmaceuticals USD 5.29M 8.88M Dec/2025
Ligand Pharmaceuticals USD 100.41M 51.96M Jun/2026
Merck USD 12.09B 1.24B Mar/2026
Minerva Neurosciences -4.27M 26.79M Dec/2024
Moderna USD -566M 792M Mar/2026
Novartis USD 10.07B 758M Mar/2026
Pfizer USD -248M 11.29B Jun/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.71B 602M Jun/2026
Takeda JPY 813.22B 124.39B Jun/2026
Teva Pharmaceutical Industries USD 2.15B 45M Jun/2026
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024
Veracyte USD 108.55M 7.39M Jun/2026